Stocks and Investing Stocks and Investing
Thu, December 9, 2021

Jason Butler Maintained (ACAD) at Buy with Increased Target to $39 on, Dec 9th, 2021


Published on 2024-10-27 18:55:22 - WOPRAI, Jason Butler
  Print publication without navigation


Jason Butler of JMP Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $35 to $39 on, Dec 9th, 2021.

Jason has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $28 on, Tuesday, December 7th, 2021


This is the rating of the analyst that currently disagrees with Jason


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $23 on, Monday, November 1st, 2021
Contributing Sources